Waiting to Treat the Cancer

It would be a race between the leukemia returning and the insurance company approving the procedure that could keep it at bay permanently.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Leukemia Transplants Bone Marrow Health Insurance and Managed Care Chemotherapy Testicles Cancer Source Type: news

Related Links:

We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Abstract The natural history of mantle cell lymphoma (MCL) is a continuous process with the vicious cycle of remission and recurrence. Because MCL cells are most vulnerable before their exposure to therapeutic agents, front-line therapy could eliminate MCL cells at the first strike, reduce the chance for secondary resistance, and cause long-term remissions. If optimized, it could become an alternative to cure MCL. The key is the intensity of front-line therapy. Both the Nordic 2 and the MD Anderson Cancer Center HCVAD trials, with follow-up times greater than 10 years, achieved long-term survivals exceeding 1...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Exp Clin Cancer Res Source Type: research
Publication date: Available online 9 November 2017Source: Seminars in Cancer BiologyAuthor(s): Christian Flotho, Sebastian Sommer, Michael LübbertAbstractMyelodysplastic syndrome (MDS) is a clonal bone marrow disorder, typically of older adults, which is characterized by ineffective hematopoiesis, peripheral blood cytopenias and risk of progression to acute myeloid leukemia. Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasm occurring in young children. The common denominator of these malignant myeloid disorders is the limited benefit of conventional chemotherapy and a particular resp...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Mozaffar Aznab, Mansour KhazaieJournal of Cancer Research and Therapeutics 2018 14(3):703-705 Myeloid sarcoma can be occurred bofore acute myeloid leukemia, concomitantly, at relapse or after allogenic stem cell transplantation, rarely. In this investigation, we reported a 38-year-old woman with a history of AML relapsed 9 months after allo-SCT as an MS in the bilateral breast. She underwent bilateral mastectomy. The patient was a candidate for systemic chemotherapy. An intermediate dose of cytarabine with mitoxantrone was considered for the patient, and it was repeated at the specified intervals. Currently, the patient i...
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
. Liesveld Acute myeloid leukemia (AML) is a disease that affects adults aged 65 years and above, and survival in this population is poor. Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for these patients but is underutilized due to frequent comorbidities and perceived higher risk of treatment-related mortality and non-relapse mortality. Increasing data supports the utility of allo-HCT in fit older patients after intensive chemotherapy resulting in improvement of outcomes. With the development of reduced intensity and non-myeloablative conditioning regimens that are associate...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusion: A novel methodology was used to quantify bone marrow activity portrayed by FDG-PET/CT for the whole skeleton of MM patients. The significant decrease in GSUVmean and GSUVmax uptake from pre- to post-treatment in the HDT group shows that the high dose treatment was likely successful to significantly decrease the cancer cells in the bone marrow of those patients.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
The concept of adoptive cell therapy to treat cancers originated with the advent of high dose chemotherapy followed by allogenic bone marrow transplantation (allo-BMT) for patients with hematologic malignancies. What would become clear over time was that the T cells present in the donor graft could mediate both a deleterious graft versus host disease (GvHD) as well as a beneficial graft versus leukemia (GvL) [1]. In the former, T cells recognize antigens on normal host tissues as foreign and attack, in the latter, donor T cells recognize antigens on host hematopoietic cells including residual leukemia tumor cells eliminati...
Source: Best Practice and Research. Clinical Haematology - Category: Hematology Authors: Tags: Preface Source Type: research
Blinatumomab, a bispecific T-cell engager antibody construct targeting CD19, has been shown to improve the outcome in patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). Treatment with blinatumomab demonstrated significant survival benefit over chemotherapy, supporting its use as a bridge therapy to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Unfortunately, following initial response, approximately 50% of responding patients eventually relapse. At the time of failure, the majority of patients have CD19-positive blasts, yet a concerning number of CD19-negative relapses has been reported.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research
Blinatumomab, a bispecific T-cell engager antibody construct targeting CD19, has been shown to improve the outcome in patients with relapsed and/or refractory B-cell acute lymphoblastic leukemia. Treatment with blinatumomab demonstrated significant survival benefit over chemotherapy, supporting its use as a bridge therapy to allogeneic hematopoietic stem cell transplantation. Unfortunately, following initial response, approximately 50% of responding patients eventually relapse. At the time of failure, the majority of patients have CD19-positive blasts, yet a concerning number of CD19-negative relapses has been reported.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research
Researchers reported encouraging results for a stem cell transplant for multiple sclerosis (MS) that some doctors and patients hope will be a breakthrough for MS treatment. In a presentation at the European Society for Bone and Marrow Transplantation held in Lisbon, Portugal, scientists said that people with certain forms of MS showed fewer relapses after receiving a stem cell transplant for MS than those who received other treatments. The study involved 110 people with relapsing multiple sclerosis, a condition in which cells in the immune system start to inexplicably attack the critical covering that protects nerve cells ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized healthytime medicine Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Health Insurance | Insurance | Insurers | Leukemia | Managed Care | Transplants